NCT05991388 - A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

210

Participants

Timeline

Start Date

May 2, 2024

Primary Completion Date

May 1, 2031

Study Completion Date

May 1, 2033

Conditions

B-cell Non Hodgkin Lymphoma

Interventions

DRUG

Odronextamab

CD20xCD3 bispecific antibody

DRUG

Loncastuximab tesirine

CD-19-directed antibody-drug conjugate

DRUG

Rituximab

Modified R-ICE chemotherapy

DRUG

Ifosfamide

Modified R-ICE chemotherapy

DRUG

Carboplatin

Modified R-ICE chemotherapy

DRUG

Etoposide

Modified R-ICE chemotherapy

DRUG

Etoposide Phosphate

Modified R-ICE (Treatment Arm II)

DRUG

Dexamethasone

Modified R-ICE chemotherapy

BIOLOGICAL

CAR T-cells (TBC)

Modified R-ICE chemotherapy

Trial Locations (3)

RECRUITING

Birmingham Children's Hospital, Birmingham

RECRUITING

Bristol Royal Hospital for Children, Bristol

RECRUITING

Royal Manchester Children's Hospital, Manchester